[1] Liu Y, Yuan Y, Zhang F, et al. Outcome of multidisciplinary treatment of peripheral primitive neuroectodermal tumor[J]. Scientific Reports, 2020,20(10):15656.
[2] Woeste M R, Bhutiani N, Hong Y K, et al. Primitive neuroectodermal tumor incidence, treatment patterns, and outcome: An analysis of the National Cancer Database[J]. Journal of Surgical Oncology, 2020,122(6):1145-1151.
[3] Gao L, Zhu Y, Shi X, et al. Peripheral primitive neuroectodermal tumors: A retrospective analysis of 89 cases and literature review[J]. Oncology Letters, 2019,18(6):6885-6890.
[4] Demir A, Gunluoglu M Z, Dagoglu N, et al. Surgical Treatment and Prognosis of Primitive Neuroectodermal Tumors of the Thorax[J]. Journal of Thoracic Oncology, 2009,4(2):185-192.
[5] Becker R G, Gregianin L J, Galia C R, et al. What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group – EWING1[J]. Bmc Cancer, 2017,17(1):420.
[6] Shunsuke I, Yoichi I, Masahiro N, et al. Primary epidural extra-osseous ewing sarcoma/peripheral primitive neuroectodermal tumor of the cervical spine curatively treated by surgery and adjuvant chemoradiotherapy: A case report and review of the literature[J]. Interdisciplinary Neurosurgery, 2020,23.
[7] Gaspar N, Hawkins D S, Dirksen U, et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration[J]. Journal of Clinical Oncology, 2016,33(27):3036-3046.
[8] Scurr, M. How to Treat the Ewing's Family of Sarcomas in Adult Patients[J]. Oncologist, 2006,11(1):65-72.
[9] Galindo C R, Spunt S L, Pappo A S. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future.[J]. Pediatric Blood & Cancer, 2010,40(5):276.
[10] Ben Kridis W, Toumi N, Chaari H, et al. A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?[J]. Reviews on Recent Clinical Trials, 2017,12(1):19-23.
[11] Schoffski P, Blay J Y, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma[J]. Curr Opin Oncol, 2020,32(4):321-331.
[12]Fleuren E D, Roeffen M H, Leenders W P, et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas[J]. Int J Cancer, 2013,133(2):427-436.
[13] Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020,21(3):446-455.
[14] Ayako, Takigami, Hideaki, et al. Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung.[J]. Internal medicine (Tokyo, Japan), 2019,58(9):1335-1339.
[15] Tawbi H A, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial[J]. Lancet Oncology, 2017,18(11):1493-1501.
[16] D'Angelo S P, Mahoney M R, Van Tine B A. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials[J]. Lancet Oncology, 2018,19(3):416-426.
[17] Motz G T, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales[J]. Nature Reviews Immunology, 2011,11(10):702-711.
[18] Yang J, Jing Y, Liu B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity[J]. Frontiers in Immunology, 2018,9:978.
[19] F B, F M, Tks B, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial[J]. The Lancet Oncology, 2019,20(6):837-848.
[20] Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial[J]. Journal for ImmunoTherapy of Cancer, 2020,8(2):11515.
[21] George S, Merriam P, Maki R G. Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas[J]. Journal of Clinical Oncology, 2009,27(19):3154-3160.
[22] Goedegebuure R, Klerk L, Bass A J, et al. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?[J]. Frontiers in Immunology, 2019,9:3107.
[23] Crocenzi T, Cottam B, Newell P, et al. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma[J]. Journal for Immunotherapy of Cancer, 2016,4:45.
[24] Ma K, Lu Y, Jiang S, et al. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis[J]. Frontiers in Pharmacology, 2018,9:1430.
[25] Su Q, Zhu E C, Wu J B, et al. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis[J]. Frontiers in Immunology, 2019,10:108-123.
[26] Tilda, Passat, Yann, et al. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].[J]. Bulletin Du Cancer, 2018,105(11):1033-1041.